CR-1-31-B free base

CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor.

For research use only. Not for human or veterinary use.

Target Eukaryotic Initiation Factor (eIF) Apoptosis

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

CR-1-31-B structure

CAS No.: 1352914-52-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 898.00	BP-00752-10mg	In stock	Get quote
25 mg	USD 1,565.00	BP-00752-25mg	In stock	Get quote
50 mg	USD 3,098.00	BP-00752-50mg	In stock	Get quote
100 mg	Inquire	BP-00752-100mg	In stock	Inquire
250 mg	Inquire	BP-00752-250mg	In stock	Inquire

Custom Size Bulk Inquiry

Description

CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.

Biological activity

Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC50 <1 nM for PI3K p110α).

Identifiers

SMILES: O=C([C@H]([C@H]1C2=CC=CC=C2)[C@@H](O)[C@]3(O)[C@@]1(C4=CC=C(OC)C=C4)OC5=CC(OC)=CC(OC)=C35)NOC
InChIKey: KLSIFOJPWJBRFH-GWNOIRNCSA-N

Specifications

MW (average): 507.5318
Formula: C₂₈H₂₉NO₈
CAS No.: 1352914-52-3
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 230 mg/mL

Documents

References

[1]. Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32(17):2179-2188.

[2]. Cao Y, et al. Targeting eIF4A using rocaglate CR 1 31B sensitizes gallbladder cancer cells to TRAIL mediated apoptosis through the translational downregulation of c FLIP. Oncol Rep. 2021;45(1):230-238.

[3]. Langlais D, et al. Rocaglates as dual-targeting agents for experimental cerebral malaria. Proc Natl Acad Sci U S A. 2018;115(10):E2366-E2375.

[4]. Skofler C, et al. Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma. Cells. 2021;10(2):301. Published 2021 Feb 2.

[5]. Chan K, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10(1):5151. Published 2019 Nov 13.

Same target

Search Eukaryotic Initiation Factor (eIF)

Same research area

Search Cancer